Please assess the completion status of the following clinical trial:

Trial Title: Trial of Verapamil in Chronic Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting to the Massachusetts Eye and Ear Sinus Center~2. Age 18-80 yrs old~3. Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria~Exclusion Criteria:~1. Patients with the following comorbidities:~   * GI Hypomotility~  * Heart Failure~  * Liver Failure~  * Kidney Disease~  * Muscular Dystrophy~  * Pregnant or Nursing Females~  * Steroid Dependency~2. Patients taking the following medications:~   * Aspirin~  * Beta-blockers~  * Cimetidine(Tagamet)~  * Clarithromycin(Biaxin)~  * Cyclosporin~  * Digoxin~  * Disopyramide(Norpace)~  * Diuretics~  * Erythromycin~  * Flecainide~  * HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir)~  * Quinidine~  * Lithium~  * Pioglitazone~  * Rifampin~  * St Johns Wort~3. Patients with cardiac or conduction abnormality picked up by screening EKG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
- Control (Type: PLACEBO_COMPARATOR): Placebo, capsules for oral administration, TID, for 8 weeks
- Open Label (Type: EXPERIMENTAL): Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).